Anatara Lifesciences Secures AU$1.2 million to Advance Anti-Obesity Project

Anatara Lifesciences (ASX: ANR), a developer of evidence-based health solutions, has successfully raised AU$1.2 million through a two-tranche placement of 100 million shares at AU$0.012 each. The issue price reflects a discount of 22.8% on the 15-day VWAP and 27.8% on the 5-day VWAP. Proceeds will primarily fund the company’s Anti-Obesity Project, including pre-clinical studies, alongside general working capital and due diligence on new opportunities.

The placement received strong backing from existing and new institutional investors, with Executive Chair David Brookes and Non-Executive Director Dirk van Dissel committing AU$40,000 each, subject to shareholder approval at the November 2025 AGM. he placement was managed and coordinated exclusively by Taylor Collison Limited as Lead Manager and Bookrunner.

With this capital injection, Anatara is well-positioned to progress its pipeline of gastrointestinal-focused therapies, expand on the GaRP project, and evaluate additional strategic opportunities, reinforcing its commitment to creating value for shareholders and addressing unmet health needs

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com